Issue of Share Options / PDMR Shareholdings

Diaceutics

23/07/2025 07:00

RNS Number : 0266S

Diaceutics PLC

23 July 2025

 

Diaceutics PLC

("Diaceutics" or the "Company")

 

Issue of Share Options/PDMR Shareholdings

New York, Belfast and London, 23 July 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces the issue of 1,886,357 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.

Share Options were granted as follows:

 

Name
Number of Share Options granted
Total no. of ordinary shares under option post grant
% of existing issued share capital
Performance Period
Ryan Keeling, CEO
271,688
1,339,298
1.58%
3 years from 22 July 2025
Nick Roberts, CFO
194,063
619,335
0.73%
3 years from 22 July 2025
Jordan Clark, CDO
189,750
329,497
0.39%
3 years from 22 July 2025
Jillian Beggs, CCO and PDMR
83,771
188,851
0.22%
3 years from 22 July 2025
Sandra Blake, CPO and PDMR
86,250
162,586
0.19%
3 years from 22 July 2025
Susanne Munksted, CPMO and PDMR
88,187
323,423
0.38%
3 years from 22 July 2025
Other employees (64 persons)
972,648
3,248,476
3.83%
3 years from 22 July 2025

 

 

For the Executive Directors, Jordan Clark, Ryan Keeling and Nick Roberts, the Share Options vest on a sliding scale up to 100%, where vesting is subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return ("TSR"), the revenue Compound Annual Growth Rate ("CAGR") and Adjusted EBITDA Margin. For all other employees, the Share Options vest after three years from the date of grant dependent upon continual employment and satisfactory employee performance.

 

The Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate, having regard to overall Company performance and wider shareholder experience.

The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.

Following this grant, the total number of share options outstanding in the Company is 6,211,466 representing approximately 7.32% of its current issued share capital of 84,812,636.

 

Enquiries: 

Diaceutics PLC
Ryan Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer
Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com
Canaccord Genuity Limited (Nomad & Broker)
Tel: +44 (0)20 7523 8000
Simon Bridges, Andrew Potts, Harry Rees


 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
1. Ryan Keeling
CEO
2. Nick Roberts
CFO
3. Jordan Clark
CDO
4. Jillian Beggs
CCO
5. Sandra Blake
CPO
6. Susanne Munksted
CPMO
2
Reason for notification
a.
Position/Status
As above
b.
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Diaceutics plc
b.
LEI
213800VEWQBB39ZB8J81
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Ordinary shares of 0.2p each
b.
Identification Code
ISIN: GB00BJQTGV64
c.
Nature of the transaction
Grant of share options
d.
Price(s) and volume(s)
Price(s)
Volume(s)
1.
Exercise price of 0.2p per share
271,688
2.
Exercise price of 0.2p per share
194,063
3.
Exercise price of 0.2p per share
189,750
4.
Exercise price of 0.2p per share
83,771
5.
Exercise price of 0.2p per share
86,250
6.
Exercise price of 0.2p per share
88,187
e.
Date of the transaction
22 July 2025
f.
Place of the transaction
Outside a trading venue


 

  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHFZGZNKZMGKZG